BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11244323)

  • 1. Treatment of advanced stage Hodgkin's disease.
    Tesch H; Sieber M; Diehl V;
    Oncology; 2001; 60(2):101-9. PubMed ID: 11244323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary treatment of advanced Hodgkin's disease].
    Illés A; Udvardy M; Molnár Z
    Orv Hetil; 2005 Jan; 146(5):195-202. PubMed ID: 15773586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
    Hehn ST; Miller TP
    Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
    J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
    Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
    J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
    Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H
    J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal BG; Marcus R; Brecher M; Ternberg J; Behm FG; Cantor A; Wharam M; Chauvenet A
    J Clin Oncol; 1991 Sep; 9(9):1591-8. PubMed ID: 1714950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
    Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
    J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
    Carde P; Hagenbeek A; Hayat M; Monconduit M; Thomas J; Burgers MJ; Noordijk EM; Tanguy A; Meerwaldt JH; Le Fur R
    J Clin Oncol; 1993 Nov; 11(11):2258-72. PubMed ID: 7693881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Our experiences in treating patients with Hodgkin disease in the last decade].
    Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
    Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.
    Santoro A; Bonadonna G; Valagussa P; Zucali R; Viviani S; Villani F; Pagnoni AM; Bonfante V; Musumeci R; Crippa F
    J Clin Oncol; 1987 Jan; 5(1):27-37. PubMed ID: 2433409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
    Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
    J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.